Article
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
Haematologica - 1 Jun 2011
Quintás-Cardama Alfonso, Kantarjian Hagop, O'Brien Susan, Jabbour Elias, Borthakur Gautam, Ravandi Farhad, Verstovsek Srdan, Shan Jianqin, Cortes Jorge
Abstract excerpt
We investigated the impact of carrying more than one BCR-ABL1 mutation in 207 patients with chronic myeloid leukemia (102 chronic, 61 accelerated, and 44 blast phase) post-imatinib failure. Seven (8%) of 92 patients carrying mutations had more than one mutation: 4 (4%) in chronic phase, 2 (2%) in accelerated phase, and one (1 %) in blast phase. The cytogenetic response rate to second generation TKIs for patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.